Rein Therapeutics

Timeline

1. May 18, 2026 Raise Follow-on offering: $57.5M (total, as published), announced May 18, 2026. Source: company release on GlobeNewswire. source ↗
2. Apr 30, 2026 Raise Follow-on offering: $50M (total, as published), announced Apr 30, 2026. Source: SEC filing. source ↗
3. Feb 2, 2026 Trial start 2: A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis source ↗
4. Jul 6, 2023 Trial start Phase 1: A Study to Evaluate LTI-03 in Newly Diagnosed Idiopathic Pulmonary Fibrosis (IPF) Patients source ↗
5. Sep 26, 2020 Trial start Phase 2: A Study to Evaluate LTI-01 in Patients With Infected, Non-draining Pleural Effusions source ↗
6. Jan 20, 2020 Trial start Phase 1: Safety, Tolerability and Pharmacokinetic Study of LTI-03 in Healthy Adult Subjects source ↗

Upcoming milestones

• Sep 30, 2027 (ESTIMATED) · 2 · A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis · NCT06968845

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Raised: $107.5M. Last 2 years.

• May 18, 2026 Follow-on offering: $57.5M (total, as published), announced May 18, 2026. Source: company release on GlobeNewswire. source ↗
• Apr 30, 2026 Follow-on offering: $50M (total, as published), announced Apr 30, 2026. Source: SEC filing. source ↗

Clinical trials (lead sponsor) 4